US20250282789
2025-09-11
Chemistry; metallurgy
C07D487/08
The invention introduces a novel crystalline form of a specific chemical compound, identified as ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone. This form is intended for use in pharmaceutical compositions and offers potential benefits in treating a range of diseases. The crystalline form is particularly significant due to its improved material properties which enhance its suitability for pharmaceutical applications.
The compound acts as an inhibitor of protein kinases, specifically targeting the enzyme Janus Kinase (JAK). This makes it a valuable therapeutic option for conditions requiring immunosuppression, such as organ transplants and autoimmune diseases like lupus and multiple sclerosis. The crystalline form's stability and polymorphic characteristics play a crucial role in its efficacy and safety as a drug.
Crystalline forms are generally preferred in pharmaceuticals due to their superior stability over noncrystalline forms. They exhibit different physical and chemical properties that can affect drug storage, stability, and bioavailability. The invention focuses on the polymorphic behavior of the compound, which influences its mechanical properties, solubility, and overall effectiveness as a medication.
Various techniques can be employed to obtain polymorphs of the compound, such as melt recrystallization, solvent recrystallization, and vapor diffusion. These methods help identify different crystalline solid forms, each with unique solid-state properties. Such diversity allows for selecting the optimal form for specific manufacturing and therapeutic needs.
The invention details specific characteristics of the crystalline form through techniques like X-ray powder diffraction and Raman spectroscopy. It also describes potential solvent systems for crystallization, including acetone and methanol. These characterizations ensure that the crystalline form meets the necessary requirements for pharmaceutical development and application.